C. Shadle

发表

A Double‐Blind, Placebo‐Controlled Evaluation of the Effect of Oral Doses of Rizatriptan 10 mg on Oral Contraceptive Pharmacokinetics in Healthy Female Volunteers

M. Goldberg, G. Liu, C. Shadle, 2000, Journal of clinical pharmacology.

Lack of Pharmacokinetic and Pharmacodynamic Interaction between Rizatriptan and Paroxetine

M. Goldberg, D. Musson, K. Birk, 1999, Journal of clinical pharmacology.

Pharmacokinetics of Oral Dexamethasone and Midazolam When Administered With Single‐Dose Intravenous 150 mg Fosaprepitant in Healthy Adult Subjects

T. Marbury, D. Panebianco, L. Caro, 2011, Journal of clinical pharmacology.

A Single‐Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects

D. Tatosian, Yang Liu, M. Murphy, 2012, Clinical pharmacology in drug development.

Rizatriptan, a Novel 5‐HT1B/1D Agonist for Migraine: Single‐ and Multiple‐Dose Tolerability and Pharmacokinetics in Healthy Subjects

T. Olah, M. Goldberg, D. Panebianco, 2000, Journal of clinical pharmacology.

Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone

J. Wagner, J. Butterton, Hwa-ping Feng, 2014, European Journal of Clinical Pharmacology.

Evaluation of Potential Inductive Effects of Aprepitant on Cytochrome P450 3A4 and 2C9 Activity

T. Bradstreet, Yih Lee, K. Petty, 2004, Journal of clinical pharmacology.

Equivalent Dynamic Human Brain NK1‐Receptor Occupancy Following Single‐Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging

G. Bormans, K. Van Laere, R. Hargreaves, 2012, Clinical pharmacology and therapeutics.

Effect of Aprepitant 40 mg on Cyto - chrome P-450 2C9 Activity: A Random- ized, Double-Blind, Placebo-Controlled, Parallel-Group Study in Healthy Young Adults

D. Panebianco, M. Murphy, Judith K. Evans, 2009 .

Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of a novel, convenient formulation.

M. Goldberg, J. McCrea, A. S. Yuan, 2000, International journal of clinical pharmacology and therapeutics.

Lack of Effect of Aprepitant or Its Prodrug Fosaprepitant on QTc Intervals in Healthy Subjects

T. Marbury, D. Panebianco, M. Murphy, 2009, Anesthesia and analgesia.

Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone

J. Wagner, J. Butterton, Hwa-ping Feng, 2014, European Journal of Clinical Pharmacology.